GlobeNewswire by notified

Philips and Gibraltar Health Authority announce 16-year strategic partnership, transforming patient imaging and cardiac care at St Bernard’s Hospital

Share

March 07, 2023

For the first time, patients will no longer need to travel abroad for treatment of acute cardiac diseases, as the Gibraltar Health Authority prepares to provide local coronary angiography and angioplasty services in a new interventional cardiac suite

Amsterdam, the Netherlands and Gibraltar – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the Gibraltar Health Authority, today announced they have signed a long-term strategic partnership continuing their long-standing relationship and marking ambitions to advance radiology and cardiology patient care. As part of the agreement, the building of a brand-new interventional cardiac suite (cath lab) will commence later this year. The construction and installation of this specialist equipment will take approximately 9-12 months and will be accompanied by a service agreement to ensure ongoing maintenance of the equipment.

Gibraltar’s newly improved services will bring sustainable benefits for patients at St Bernard’s Hospital, with developments expected to lead to more cardiac patients receiving local treatment, instead of traveling across the border to neighboring Spain. Expected clinical outcomes include reduced length of stays for such patients, relieving pressure on demand for hospital beds and ambulance transport services, and improvement in 30-day mortality rates.

The new interventional suite will bring St Bernard’s Hospital’s services up to full operating capacity, allowing more patients to receive a range of cardiology treatments such as coronary angioplasty, catheterization to treat artery blockages and minimally invasive replacement of heart valves. In parallel, existing Philips systems within the hospital will be upgraded with the latest technology, including the replacement of equipment in two X-ray rooms, a fluoroscopy room for real-time moving X-ray imagery and ultrasound systems. As part of the agreement, a new CT system will reduce downtime and delays in diagnostics whilst creating opportunities for St Bernard’s cardiology and radiology teams to further expand services. This could see the Gibraltar Health Authority continue to bring care closer to home for future patients, such as through the availability of coronary CT scanning.

“This new chapter in our partnership with the Gibraltar Health Authority will give both clinicians and the community of Gibraltar access to innovative technologies beyond the next decade,” said Mark Leftwich, Managing Director for Philips UK and Ireland. “For the first time, clinical staff will be able to manage acute cardiac diseases, such as heart attacks, in a purpose-built suite, whilst Philips imaging systems and informatics will enable faster scanning time and enhanced collaboration. This will help create more efficiency and capacity within the departments and improved image quality will support safer diagnosis.” 

Professor Patrick Geoghegan OBE, Director General Gibraltar Health Authority said: “We are delighted to renew and strengthen our relationship with Philips with this new partnership. The impact that this new diagnostic equipment will have on our operation and on the quality of care we will be able to provide for our community is huge. Gibraltar Health Authority continues to strive to provide the best healthcare to the people of Gibraltar.”

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
E-mail: joost.maltha@philips.com

Dominique Monaghan
Philips UK and Ireland Press Office
Tel: +44 7975 755 514
E-mail: dominique.monaghan@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Gibraltar Health Authority
The GHA delivers Primary, Secondary and Mental Health Care in Gibraltar. It uses a Healthcare model closely linked to the NHS, and for this purpose some tertiary referrals are delivered in the NHS as well as in Spanish hospitals due to the proximity.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Storaktionærmeddelelse25.3.2023 14:30:37 CET | pressemeddelelse

Årets meddelelse nr. 20 Dato: 25. marts 2023 Storaktionærmeddelelse Det skal herved meddeles, at Pharma Equity Group A/S har modtaget meddelelse om at NK Invest ApS ejerandel, både direkte og indirekte via dennes ejerskab af Selskabet af 25. marts DK ApS og Selskabet af 25. marts II ApS, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 % af den udstedte aktiekapital i Pharma Equity Group A/S. Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: peter.ole.jensen@pharmaequitygroup.com. Med venlig hilsen Pharma Equity Group A/S På bestyrelsens vegne

FCB Tops 2023 WARC Rankings for Creative Effectiveness24.3.2023 21:41:59 CET | Press release

FCB awarded #1 Creative Agency & #1 Campaign for Effectiveness in WARC Effective 100 NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- FCB was a top performer in the 2023 WARC Rankings, earning recognition as the #1 Creative Agency for Effectiveness in the WARC Effective 100, among other distinctions. Numerous FCB campaigns were honored as well, including Michelob ULTRA’s “Contract for Change,” which ranked as the #1 Campaign for Effectiveness. “Creative is the business and the business is creative. To separate the two does a disservice to the industry. We will continue to partner with our clients to create work that is both effective in the moment and impactful long term. FCB is honored that this Timely and Timeless approach to work is being recognized by WARC,” said Susan Credle, FCB Global Chair & Global CCO. In the Effective 100, FCB New York was named the #1 Creative Agency for Effectiveness, joined by two additional FCB agencies, with FCB Chicago ranking #4 and FCB Toronto ranking #7,

Ordinary and Extraordinary General Meeting of April 12, 202324.3.2023 21:30:00 CET | Press release

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches pari

TGS: Approval of 2022 Financial Result24.3.2023 20:03:58 CET | Press release

Oslo, Norway (24 March 2023) – The Board of Directors of TGS ASA has today approved the financial statements for 2022. The financial statements were prepared in accordance with IFRS. Please see the attachment for a summary of changes from the preliminary annual accounts announced on 9 February 2023. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS.com (http://www.tgs.com) or contact: Sven Børre Larsen CFO Tel: +47 90 94 36 73 E-mail: investor@tgs.com Attachment TGS Annual Accounts 2022 update

Nokia Corporation: Repurchase of own shares on 24.03.202324.3.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 24 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 24.03.2023 Espoo, Finland – On 24 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL306,0764.31CEUX7,3924.31AQEU2,6084.31TQEX6,3244.32Total322,4004.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and